Design and Synthesis of USP1 Inhibitors: In Vivo Validation in TNBC

Yaxin Teng published a dataset on figshare on 2026-04-29 describing the design and synthesis of USP1 inhibitors. The data likely contains results from in vitro assays and in vivo xenograft studies demonstrating synergistic antitumor activity with PARP inhibitors in triple-negative breast cancer models. The dataset is 4.5 KB in size and is available in CSV format under a CC-BY-NC-4.0 license.

Use Cases

• Analyzing structure-activity relationships based on the described scaffold-hopping core and compound optimization.
• Evaluating in vivo efficacy based on the described xenograft studies and tumor growth inhibition data.
• Studying drug combination synergy based on the described results for compound 57 and Olaparib.
• Assessing pharmacokinetic properties based on the described human liver microsomal stability and oral bioavailability data.

Strengths

• Dataset includes specific quantitative results, such as nanomolar USP1-UAF1 inhibition and 76% oral bioavailability in rats.
• Data is supported by multiple experimental methods, including in vitro assays, in vivo xenograft studies, transcriptomic analysis, and Western blot.
• The dataset is openly available under a CC-BY-NC-4.0 license, facilitating academic reuse.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is very small at 4.5 KB, indicating a limited scope of data.

Provenance

Source

figshare

Collection Method

Likely contains experimental results from medicinal chemistry and pharmacology studies.

Freshness

Last updated 2026-04-29 19:44:21; freshness should be verified.